#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14352	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2187	654.0	0	.	n	.	0	A69G	SNP	69	69	A	375	375	G	789	G	749	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14352	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2187	654.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1756	1756	T	858	T,C	795,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14352	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2187	654.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1490	1490	C	866	C,A	815,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26450	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3578	736.5	0	.	n	.	0	C1176T	SNP	1176	1176	C	1587	1587	T	767	T,C	728,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26450	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3578	736.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1748	1748	A	928	A,G	858,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26450	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3578	736.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2382	2382	C	901	C	835	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26450	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3578	736.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2456	2456	A	887	A	837	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26450	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3578	736.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	3008	3008	C	797	C	750	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	1926	folP	852	852	99.88	folP.l15.c4.ctg.1	1504	127.5	0	.	p	.	0	E151K	NONSYN	451	453	GAA	743	745	AAA	187;188;189	A;A;A	179;177;179	.	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	1926	folP	852	852	99.88	folP.l15.c4.ctg.1	1504	127.5	1	SNP	p	R228S	1	.	.	682	684	AGC	974	976	AGC	223;223;223	A;G,T;C	210;205,1;206	folP.WHO_K_01359c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5216	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3404	152.8	0	.	p	.	0	K261del	DEL	781	781	A	1086	1086	A	175	A	166	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5216	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3404	152.8	1	SNP	p	S91F	0	.	.	271	273	TCC	576	578	TCC	175;177;177	T;C,T;C	161;164,1;166	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5216	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3404	152.8	1	SNP	p	D95G	0	.	.	283	285	GAC	588	590	GAC	180;182;183	G;A,G;C	167;167,1;170	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5216	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3404	152.8	1	SNP	p	D95N	0	.	.	283	285	GAC	588	590	GAC	180;182;183	G;A,G;C	167;167,1;170	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1682	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1326	126.4	1	SNP	p	G45D	0	.	.	133	135	GGC	433	435	GGC	212;209;210	G;G;C	202;198;200	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	878	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	983	89.0	0	.	n	.	0	A197.	DEL	197	197	A	532	532	A	211	A	198	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4984	parC	2304	2304	99.91	parC.l15.c30.ctg.1	2985	166.4	1	SNP	p	D86N	0	.	.	256	258	GAC	626	628	GAC	197;196;199	G;A;C	178;173;182	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4984	parC	2304	2304	99.91	parC.l15.c30.ctg.1	2985	166.4	1	SNP	p	S87R	0	.	.	259	261	AGT	629	631	AGT	198;198;197	A;G;T	181;182;177	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4984	parC	2304	2304	99.91	parC.l15.c30.ctg.1	2985	166.4	1	SNP	p	S87W	0	.	.	259	261	AGT	629	631	AGT	198;198;197	A;G;T	181;182;177	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4984	parC	2304	2304	99.91	parC.l15.c30.ctg.1	2985	166.4	1	SNP	p	S87I	0	.	.	259	261	AGT	629	631	AGT	198;198;197	A;G;T	181;182;177	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4984	parC	2304	2304	99.91	parC.l15.c30.ctg.1	2985	166.4	1	SNP	p	S88P	0	.	.	262	264	TCC	632	634	TCC	198;199;198	T;C;C	180;180;181	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4158	parE	1986	1986	100.0	parE.l6.c30.ctg.1	2534	163.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1484	1486	GGC	189;190;186	G;G;C	176;177;173	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	3878	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2375	162.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1215	1217	GCA	217;222;221	G;C;A	202;201;201	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3878	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2375	162.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1218	1220	ATC	220;220;221	A;T;C	203;204;204	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3878	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2375	162.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1230	1232	GTG	230;227;228	G;T;G	210;205;208	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3878	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2375	162.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1230	1232	GTG	230;227;228	G;T;G	210;205;208	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3878	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2375	162.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1734	1736	ACC	182;183;183	A;C;C	163;168;167	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3878	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2375	162.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1788	1790	GCG	176;178;178	G;C;G	160;146;152	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3878	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2375	162.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1788	1790	GCG	176;178;178	G;C;G	160;146;152	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3878	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2375	162.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1911	1913	GGC	182;184;182	G;G;C	171;174;170	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3878	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2375	162.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1920	1922	GGC	178;178;178	G,C;G;C,T	165,1;165;165,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3878	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2375	162.6	1	SNP	p	L552S	0	.	.	1654	1656	CTG	1938	1940	CTG	172;174;175	C,G;T;G	130,4;126;137	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5830	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3148	184.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1559	1561	CCG	223;222;222	C;C;G	196;203;196	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2192	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1663	131.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	501	501	C	169	C	154	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2840	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1557	181.2	0	.	p	.	0	N38E	NONSYN	112	114	AAT	488	490	GAA	266;269;269	G;A;A	248;251;251	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2840	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1557	181.2	0	.	p	.	0	N134D	NONSYN	400	402	AAT	776	778	GAT	231;231;231	G;A;T	220;215;216	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2840	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1557	181.2	0	.	p	.	0	P175S	NONSYN	523	525	CCA	899	901	TCA	238;238;241	T;C;A	226;224;229	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2840	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1557	181.2	0	.	p	.	0	D212del	DEL	634	634	G	1009	1009	C	214	C	198	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2840	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1557	181.2	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1025	1027	GTC	222;222;226	G;T;C	212;210;219	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2840	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1557	181.2	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1037	1039	TCT	232;233;234	T;C,T;T,C	221;223,1;226,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2840	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1557	181.2	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1355	1357	GCA	238;242;241	G;C;A	225;231;231	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2840	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1557	181.2	1	SNP	p	G120K	1	.	.	358	360	AAG	734	736	AAG	228;228;233	A,G;A,G;G,T	216,1;217,1;218,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2840	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1557	181.2	1	SNP	p	A121D	1	.	.	361	363	GAC	737	739	GAC	231;231;234	G;A,C;C	217;214,1;218	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2840	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1557	181.2	1	SNP	p	D121N	0	.	.	361	363	GAC	737	739	GAC	231;231;234	G;A,C;C	217;214,1;218	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	10696	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4859	219.6	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2011	2013	AAT	237;237;238	A;A;T	226;225;227	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1106	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1019	107.9	1	SNP	p	V57M	1	.	.	169	171	ATG	506	508	ATG	230;230;232	A;T;G	217;219;219	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
